PNC Managed Account Solutions’s Bio-Rad Laboratories Class A BIO Stock Holding History

PNC Managed Account Solutions’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$128K	Buy	+199	New	+$121K	0.03%	272

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PNC Managed Account Solutions's BIO Position: Q2 2021 in Review

PNC Managed Account Solutions opened a new position in Bio-Rad Laboratories Class A (BIO) in Q2 2021: 199 shares worth $128K. The stake represents 0.03% of the portfolio and ranks #272 among its holdings.

508 funds tracked by Wall St. Rank hold BIO as of Q2 2021.

PNC Managed Account Solutions held 199 shares of Bio-Rad Laboratories Class A worth $128K as of Q2 2021.
Bio-Rad Laboratories Class A was a new PNC Managed Account Solutions position in Q2 2021.
Bio-Rad Laboratories Class A made up 0.03% of PNC Managed Account Solutions's portfolio in Q2 2021, its #272 holding.
508 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2021.

Based on PNC Managed Account Solutions's 13F filing for Q2 2021, filed 6 Aug 2021.